For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Key Findings
The Asia-Pacific metagenomics market is anticipated to grow rapidly due to increased cancer rates, rise in investments and growing healthcare expenses and various emerging applications. In 2018, revenue of metagenomics market in APAC was valued at $xx million. By 2026, the market is expected to reach $xx million, at a CAGR of 15.92% during forecasted period 2019-2027.
Market Insights
The Japanese healthcare market is driven primarily by increasing aging population, high prevalence of cancer, high levels of affordability and access to healthcare facilities. Also, according to the ministry of health, labor and welfare report, cancer was the leading reason of death followed by heart diseases and pneumonia. Genomics is booming in China. China consists of around 30% of the world's sequencing medicine and therefore, the government before 2030 is planning to invest 60 billion yuan in nation precision initiative, which will further propel the growth of the market in China.
On the other hand, according to the Australian ministry of health, a medical industry growth plan is aimed at improving health conditions among 200,000 Australians. This program is known as the Australian Genomics Health Futures Mission. The mission will include a series of studies to tackle rare neuro diseases and cancers, to allow patients early access to clinical trials for drug testing and invest cordially with business and philanthropic interests, engaging in a dialogue with the community to understand social, legal familial and privacy impacts of genome medicine
Competitive Insights
The dominant competitors in the market are Perkin Elmer Inc., Pacific Biosciences of California, Illumina Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Enterome SA, F Hoffman La-Roche Ltd, Qiagen NV, Swift Biosciences Inc., Agilent Technologies Inc., Interagen SA, and Oxford Nanopore Technology.